25 October 2023 - NICE has published final evidence-based recommendations on the use of tirzepatide (Mounjaro) for the treatment of patients with type 2 diabetes mellitus.

Tirzepatide is recommended for the treatment of adults with type 2 diabetes mellitus alongside diet and exercise when it is insufficiently controlled only if:

• Triple therapy with metformin hydrochloride and two other oral anti-diabetic drugs is ineffective, not tolerated or contra-indicated, and
• They have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or
• They have a BMI of less than 35 kg/m2, and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related complications

Read NICE technology appraisal guidance